Int Urol Nephrol DOI 10.1007/s11255-016-1248-5

UROLOGY - REVIEW

Urological complications of uterine leiomyoma: a review of literature Gautam Dagur1 · Yiji Suh1 · Kelly Warren1 · Navjot Singh1 · John Fitzgerald2 · Sardar A. Khan1,2,3 

Received: 13 January 2016 / Accepted: 13 February 2016 © Springer Science+Business Media Dordrecht 2016

Abstract  Introduction  Uterine leiomyomas are common gynecologic tumor in reproductive-aged women, by age 50, diagnosis shared by urologist, gynecologists and radiologists. Objective  The goal of this article is to review the current literature, study the impact of leiomyoma on female lower urinary tract, examine the cause female sexual dysfunction and provide a comprehensive review of current diagnostic, imaging studies, and current treatment of leiomyoma. Methods  Clinical leiomyoma studies published from 1956 through 2015 were identified using the PubMed search engines and the key words leiomyoma, fibroid in the current literature. Impact of leiomyoma on the lower urinary tract including female sexual dysfunction was reviewed with terms of “urinary retention”, “bladder”, “urethra”, “dyspareunia”, “incontinence”, “incomplete bladder emptying”, “female sexual dysfunction”, and “lower urinary tract” to study the urological and sexual effects of leiomyoma. Literature related to leiomyoma was reviewed from 1965 to present. Results  Women with uterine leiomyomata complained of pelvic pain, menstrual irregularities, infertility, lower urinary tract symptoms and sexual dysfunction. Conclusion  Leiomyoma is a common tumor of the uterus that often clinically impacts on the lower urinary tract and

* Sardar A. Khan [email protected] 1

Department of Physiology and Biophysics, SUNY at Stony Brook, Stony Brook, NY 11794, USA

2

Department of Urology, SUNY at Stony Brook, Stony Brook, NY 11794, USA

3

HSC Level 9 Room 040 SUNY at Stony Brook, Stony Brook, NY 11794‑8093, USA



results in urological and sexual symptoms. Leiomyoma can compress and grow into and become adherent to the bladder and surrounding pelvic organs or metastasize into peritoneal organs. Leiomyoma can enlarge and compress the urinary bladder, urethra, and lower end of the ureters. Leiomyoma can cause embarrassing sexual dysfunction in females. Current literature of non-surgical and surgical therapy of leiomyoma is described. Keywords  Uterine leiomyoma · Hydronephrosis · Acute urinary retention · Hematuria · Hysterectomy · Lower urinary tract symptoms Abbreviations ECM Extracellular matrix Bcl-2 Beta cell lymphoma-2 GPER G-protein estrogen receptors AUR Acute urinary retention LUTS Lower urinary tract symptoms BN Barrington’s nucleus

Introduction Uterine leiomyomas are benign neoplasms of smooth muscle that originate in the myometrium [1]. They are also known as fibroids, referring to the amount of collagen found within the masses. Incidence of leiomyomas can be as high as 70–80 % in women by age of 50, with highest rates among African-American women [2]. Leiomyomas can become symptomatic, with greater incidence among nulliparous women. Although specific causes of uterine leiomyomas are unknown, leiomyomas may be due to hormonal and genetic factors [3, 4]. Our objective is to compile recent literature to provide a comprehensive understanding

13



of uterine leiomyoma as well as its urological manifestations and complications of the urinary tract. Clinical manifestations of uterine leiomyoma on female urinary tract have not been addressed in major textbooks.

Molecular and genetic aspects of uterine leiomyomas The specific etiology of leiomyomas is currently unknown, but studies suggest that leiomyoma may arise by phenotypic mutation of a single myometrial smooth muscle cell, which stimulates cell proliferation and results in production of excess extracellular matrix (ECM). Leiomyomas create a hyperestrogenic environment necessary for leiomyoma growth and maintenance. Leiomyomas have high concentrations of estrogen and progesterone receptors which assists in greater estradiol binding [5]. Increased estrogen and progesterone production leads to leiomyoma growth; therefore, it is not uncommon for women on oral contraceptive to see increased growth of leiomyomas [6, 7]. In the past, progesterone influenced the production of leiomyoma with apoptosis and generation of extraneous cells. However, Bulun et al. [3] suggests progesterone may have a role in the growth of leiomyomas. Highly expressed beta cell lymphoma-2 (Bcl-2) is able to prevent apoptosis. This gene is prevalent during the secretion phase of the menstrual cycle and less when progesterone is released. Increase in Bcl-2 protein may be the cause of increased cell growth by prevention of cell death [8]. ECM proliferation, in uterine leiomyomas, is upregulated by the promoter protein TGFβ3 [9] which is known to interact with dermatopontin and thrombospondin [10]. Integrin proteins play a critical role in the shape and growth of leiomyomas. The most critical integrin protein is integrin β1, which is upregulated in leiomyomas [11]. Alterations in chromosomes have been linked to leiomyoma growth. Chromosomes 6, 7, 12, and 14 are found to correlate with rates of leiomyoma growth [12]. Mehine et al. [4] suggest that there are four emerging molecular classifications: high rates of MED12 gene mutations, deletions of COL4A5-COL4A6 genes, increased HMGA2 expression, and FH inactivation. More studies are necessary to comprehend the genetic pathogenesis of uterine leiomyoma. Wu et al. state G-protein estrogen receptors (GPER) play an important role in tamoxifen-related uterine pathology, causing thickening and bleeding of the endometrium. Tamoxifen is a selective estrogen receptor modulator that functions as an agonist and antagonist depending on the target tissue. In endometrium, tamoxifen works as an estrogen receptor antagonist. Changing estrogen receptor-α and isoforms of the receptor along with G-protein-coupled receptor 30 in endometrial cells has been proven to control

13

Int Urol Nephrol

tamoxifen in cancer cell creation [13]. Although this study conducted focused primarily on breast cancer progression, there may be a correlation with uterine leiomyomas as the GPER in cancerous fibroblasts can produce collagen that eventually metastasizes to uterine walls. It is also interesting to note that elevation of estrogen levels correlate not only to breast cancer but also to uterine leiomyomas [14]. Targeting future research on GPER represents possible development for future potential uterine leiomyoma therapy.

Anatomical classification of leiomyomas Leiomyomas are divided based on location and position in the uterus (Table 1).

Clinical examination Symptoms Leiomyomas tend to be asymptomatic in most women but a third of women experience further growth and symptoms (Table 2). Physical examination Physical examination may fail to detect small leiomyomas. Palpation of leiomyoma is dependent on the anatomical Table 1  Anatomical classification of leiomyomas Extrapelvic leiomyoma

Intrapelvic leiomyoma

Round ligament myomata [15]

Intramural myomata [16] Submucosal myomata [16]  Protruding myomata [17] Subserosal myomata [18, 19] Pedunculated myomata  Subserosal [18]  Submucosal [17] Parasitic myomata [1, 20] Interstitial myomata [21] Cervical myomata [22] Broad ligament myomata [23]

Table 2  Common symptoms of uterine leiomyomas Symptoms  Menorrhagia [24]  Pelvic discomfort [25]  Dysmenorrhea [26, 27]  Infertility [28]  Miscarriage [29, 30]

Int Urol Nephrol Table 3  Imaging modalities for uterine leiomyomas

Table 4  Instrumentation for diagnosis of uterine leiomyomas

Imaging modalities Dynamic real time transvaginal ultrasound [31, 32]  With empty bladder  With bladder distension Abdominal ultrasound [31] Transrectal ultrasound [33]  With bladder distension  With empty bladder Plain radiography [19] Computerized tomography (CT) [34] CT with 3-dimensional reconstruction Magnetic resonance imaging (MRI) [34, 35] Stand up MRI with valsalva MRI with 3-dimensional reconstruction MR angiogram [36]

Instruments for diagnosing  Hysteroscopy [37]  Speculum examination [38]  Cystoscopy [39]  Diagnostic laparoscopy [40]

Hysterosalpingography [19]

 Video-urodynamics

angiogenesis occurs upon protruding onto the bladder, and contraction of the bladder ruptures these vessels which may result in hematuria. Parasitic leiomyoma dislodges from their site of origin and can travel to a different region of the body. Certain times, they can result in unilateral ureteral obstruction [43]. Uterine leiomyoma, growing superiorly, can protrude onto the ureter and result in obstruction. This may cause urine backflow and hydronephrosis. Urethral obstruction

location of leiomyoma. Bimanual pelvic examination, including rectal and pelvic examination, may reveal palpable leiomyoma with pelvic tenderness. Speculum examination and optional proctoscopy may complete the physical diagnosis.

Imaging methods Leiomyomas are often detected during a pelvic exam. However, imaging studies are utilized to identify anatomical locations, size, and impact on urinary tract (Table 3).

Instrumental exam Diagnosis for leiomyomas with instruments and videourodynamics helps identify their anatomical locations and impact on bladder-urethra and upper urinary tract (Table 4).

Urological complications of leiomyomas Pathogenesis of urological complications Urological complications may develop depending on the anatomical locations, size, growth, and the leiomyoma sarcomatous changes. Growth of a leiomyoma in the broad ligament can result in obstruction of the bladder outlet and paravaginal obstruction, resulting in urinary retention [41]. Intrapelvic leiomyoma can protrude anteriorly and inferiorly from the uterus and press onto the bladder. Leiomyomas rely on angiogenesis to allow for growth [42]. Therefore,

Several case reports describe acute urinary retention (AUR) in patients with leiomyoma [13, 44, 45]. Yazdany et al. [46] states, AUR can be caused when uterine leiomyomas cause a superior and anterior rotation of the cervix, which ultimately causes urethral or bladder-neck compression. During urination, the cervix rotates away from the urethra. Proposed mechanism relating AUR secondary to uterine leiomyomas results from obstruction of proximal urethra and bladder neck, associations with premenstrual pelvic congestion, and neuropathy of the pudendal or sacral nerves [13]. Angle variations of the bladder neck and urethral mobility demonstrate the physical differences between continent and incontinent women. Straining while in the supine position does not cause obstruction in the urethral range of motion as the average rotational angle of the bladder neck ranges from 21° to 44°, with an average of 32°. The bladder neck angle, the angle of the urethrovesical junction located behind the pubic symphysis, ranges at a normal level between 83° and 107° with an average of 95°. In contrast, continent pregnant females have different ranges of −8° to 56° with an average of 19° for the urethral mobility, and a range of 38°–80° with an average of 65° for the resting bladder neck angle. The range of urethral mobility is more limited in incontinent patients, while bladder neck angle is greater in range [47, 48]. If untreated, AUR can result in permanent damage to the detrusor muscle, resulting in bladder trabeculation, bladder diverticula, and vesicoureteral reflux [49]. Ureteral obstruction/hydronephrosis Patients with uterine leiomyoma can develop obstructive uropathy, either unilateral or bilateral secondary

13



Int Urol Nephrol

ureteral obstruction causing hydronephrosis. Mirsadraee et al. discuss 10 patients suffering from hydronephrosis. Patient complaints include menorrhagia, dysmenorrhea, pain, and mild renal impairment. In all cases, large leiomyomas compressed the ureter at the pelvic brim. Uterine artery embolization resolved the hydronephrosis and relieved ureteral obstruction, relieving symptoms as well [50]. Lai et al. [51] suggest that hypertension, resulting from obstruction of the kidneys, leads to decreased glomerular filtration rate by increased pressure in the Bowman’s capsule. More studies are necessary to determine the relationship between hypertension and hydronephrosis. Prolonged uterine prolapse, due to uterine leiomyoma, can result in hydronephrosis [52]. Lower urinary tract symptoms (LUTS) Stewart et al. present a case in which a woman experiences heavy menstrual bleeding, nocturia, and urinary frequency. Diagnostic study indicated uterine leiomyoma could potentially have caused these symptoms [53]. Parker-Autry et al. conducted a survey where patients with uterine leiomyoma experience LUTS. Study was concluded due to the location and type of leiomyoma. Patients with intramural leiomyoma and anterior fibroids had worse symptoms of LUTS. More prominent symptoms included: nocturia, urinary urgency, frequency, and incontinence [54]. It can be concluded that bladder compression due to anterior leiomyoma resulted in LUTS (Fig. 1). Vesicouterine fistula A degenerating leiomyoma or leiomyosarcoma can cause a fistula between the uterus and bladder, causing hematuria, abdominal pain, and vaginal urine leakage [39]. Fistulas may be confirmed with cystoscopy, cystogram methylene blue test, or CT scan. Surgery is the preferred treatment, utilizing omental flap interpositions in certain situations [55]. Renal failure If uterine leiomyomas are left untreated for prolonged period of time, it could result in renal failure and renal hypertension [56]. Leiomyoma may cause renal impairment with good prognosis [57].

Fig. 1  Uterine leiomyoma, identified by the arrow, compressing and adhering to the bladder presenting irritative and obstructive urinary symptoms. This can interfere with storage and emptying of the bladder

Female sexual dysfunction Masters and Johnson reported four stages of the female sexual cycle which consisted of excitement, plateau, orgasm, and resolution [59]. Female sexual response results in increased pelvic blood flow, vaginal lubrication, and clitoral and labial engorgement. Increase in pelvic blood flow is by hypogastric arterial bed [60]. Barriers to sexual function in female patients with leiomyoma include pelvic pain, dyspareunia, orgasmic disorders, decreased libido, decreased vaginal lubrication, urinary incontinence, and obstructive and irritative bladder symptoms. Sexual dysfunction can occur secondary to uterine leiomyomas when a large retroperitoneal mass impinges upon the vagina. Repetitive contact can irritate the lumen of the vagina, as projecting parietal peritoneum cause pain and discomfort [61]. Currently, there is no treatment for dyspareunia, which makes surgery an option. Eight months are needed after surgery to resume normal sexual intercourse [62]. Nerve sparing surgery of leiomyomas may preserve sexual function in females [63].

Hematuria Neurogenic bladder Hematuria may be a significant manifestation of leiomyoma, invading the bladder wall during degeneration, sarcomatous changes, and vesico-uterine fistula [39, 58].

13

Increased pressure within the bladder acts on the proprioceptive sensory receptor signals onto the Barrington’s

Int Urol Nephrol Table 5  Non-urological complications of uterine leiomyomas Non-urological complications Cystic degeneration [65] Torsion of uterine leiomyomas [40, 66] Colorectal/anal difficulty [67] Circulatory problems  Deep-vein thrombosis [68, 69]  Polycythemia [70]  Pelvic venous compression [71]  Intravenous leiomyomatosis [25, 70]  Thrombus extending into Right Heart [72]  Thrombus extending into vena cava [73]  Thrombophlebitis [74]  Edema [75] Leiomyomatosis peritonealis disseminata [76] Pregnancy complications  Miscarriage [29, 30]  Prevention of implantation/infertility [77] Uterine Prolapse [78]

nucleus (BN), within the brain. BN relays to the hypothalamus and responding back to bladder to void. Both parasympathetic and sympathetic signaling aid in the contraction of the bladder wall and relaxation of internal sphincter, resulting in micturition [64]. Disruption of the pelvic autonomic pathways can result in neurogenic bladder and voiding dysfunction. Leiomyoma can compress the bladder and increase signaling of proprioceptive sensory receptors, therefore causing increased frequency of micturition [44]. Leiomyomas can also lead to urethral obstruction depending on the location of the growth [44].

Other complications of uterine leiomyomas Other, non-urological complications may present themselves due to uterine leiomyomas (Table 5).

Treatment options

Anemia [79]

Table 6  Different treatment option for uterine leiomyomas Treatment Options Hormone therapy  Levonorgestrel-releasing intrauterine device [80]  Gonadotropin-releasing hormone agonist [81]  Progesterone-receptor modulators   Mifepristone [82]   Ulipristal acetate [83]   Asoprisnil [84]  Aromatase inhibitor   Letrozole [85] Hifu of myoma [86] Surgical procedures  Minimally invasive   Hysteroscopy [87]   Uterine artery embolization [88, 89]   MRI-guided focused ultrasound surgery [90, 91]  Invasive   Myomectomy    Open [92]    Laparoscopy [93]    Robotic [94]   Hysterectomy [53, 95] Radiofrequency ablation [96] Guizhi Fuling Formula [26]

Pre-operative preparation for surgical management of complicated uterine myomectomy or excision of leiomyoma includes indwelling Foley catheter and insertion of ureteral stents to identify and prevent ureteral injury during complicated surgery. Treatment options for management of uterine leiomyomas range from observations and medical management to invasive surgical options. The type of treatment used for a patient is dependent on several factors: age, health, symptoms, menopausal status, type of fibroids, if pregnant, and choice of future pregnancy (Table 6). Surgical controversies exist regarding best treatment options.

Summary This paper examines the current literature of clinical manifestations and impact of leiomyoma on urinary tract. Diagnostic and therapeutic options to relieve urologic symptoms are discussed. Acknowledgments  We gratefully acknowledge literature research assistance from Mrs. Wendy Isser and Ms. Grace Garey. Author’s contributions  Gautam Dagur M.S. designed, organized, and wrote the review article; corrected references; and solved queries related to scientific publications from the journals. Yiji Suh wrote the review article and designed outline. Kelly Warren Ph.D. critiqued and applied logical reasoning to the literature. Navjot Singh performed Medline searches, critiqued, and corrected the literature. John Fitzgerald M.D. retrieved and evaluated scientific information related to the article. Sardar A. Khan M.D. FRCS FACS is the corresponding author, formulated clinical concepts, reviewed the article, and corrected the references.

13

Compliance with ethical standards  Conflict of interest  The authors declare they have no conflict of interest.

References 1. Purohit P, Datta S, Narvekar N (2015) Open power morcellation. Obstet Gynaecol Reprod Med 25(7):208–209 2. Feingold-Link L et al (2014) Enhancing uterine fibroid research through utilization of biorepositories linked to electronic medical record data. J Womens Health (Larchmt) 23(12):1027–1032 3. Bulun SE et al (2015) Uterine leiomyoma stem cells: linking progesterone to growth. Semin Reprod Med 33(5):357–365 4. Mehine M et al (2014) Genomics of uterine leiomyomas: insights from high-throughput sequencing. Fertil Steril 102(3):621–629 5. Van Voorhis B (2009) A 41-year-old woman with menorrhagia, anemia, and fibroids: review of treatment of uterine fibroids. JAMA 301(1):82–93 6. Moravek MB et al (2015) Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications. Hum Reprod Update 21(1):1–12 7. Valle R, Ekpo G (2015) Pathophysiology of uterine myomas and its clinical implications. In: Tinelli A, Malvasi A (eds) Uterine myoma, myomectomy and minimally invasive treatments. Springer, Berlin, pp 1–11 8. Csatlos E et al (2015) Role of Apoptosis in the development of uterine leiomyoma: analysis of expression patterns of Bcl-2 and Bax in human leiomyoma tissue with clinical correlations. Int J Gynecol Pathol 34(4):334–339 9. Norian JM et al (2009) Transforming growth factor beta3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas. Reprod Sci 16(12):1153–1164 10. Behera MA et al (2007) Thrombospondin-1 and thrombospondin-2 mRNA and TSP-1 and TSP-2 protein expression in uterine fibroids and correlation to the genes COL1A1 and COL3A1 and to the collagen cross-link hydroxyproline. Reprod Sci 14(8 Suppl):63–76 11. Malik M, Segars J, Catherino WH (2012) Integrin beta1 regulates leiomyoma cytoskeletal integrity and growth. Matrix Biol 31(7–8):389–397 12. Medikare V et al (2011) The genetic bases of uterine fibroids; a review. J Reprod Infertil 12(3):181–191 13. Wu CQ et al (2015) Urinary retention and uterine leiomyomas: a case series and systematic review of the literature. Int Urogynecol J 26(9):1277–1284 14. Prossnitz ER, Barton M (2011) The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol 7(12):715–726 15. Harish E, Sowmya NS, Indudhara PB (2014) A rare case of round ligament leiomyoma: an inguinal mass. J Clin Diagn Res 8(10):Nj05-Nj06 16. Closon F, Tulandi T (2015) Uterine myomata: organ-preserving surgery. Best Pract Res Clin Obstet Gynaecol. doi:10.1016/j. bpobgyn.2015.09.005 17. Pavanello L et al (2015) Fibroids. In: Manfredi R, Mucelli RP (eds) MRI of the female and male pelvis. Springer, Berlin, pp 97–127 18. Suganuma I et al (2015) Autoamputation of a pedunculated, subserosal uterine leiomyoma presenting as a giant peritoneal loose body. Arch Gynecol Obstet 291(4):951–953 19. Wilde S, Scott-Barrett S (2009) Radiological appearances of uterine fibroids. Indian J Radiol Imaging 19(3):222–231

13

Int Urol Nephrol 20. Temizkan O et al (2014) A case of parasitic myoma 4 years after laparoscopic myomectomy. J Minim Access Surg 10(4):202–203 21. Zaporozhan VN (1996) Intratissue laser thermotherapy in treatment of uterine myomata. J Am Assoc Gynecol Laparosc 3(4, Supplement):S56 22. Patel P et al (2011) Handling cervical myomas. J Gynecol Endosc Surg 2(1):30–32 23. Song JY (2015) Laparoscopic resection of a rare, large broad ligament myoma. J Minim Invasive Gynecol 22(4):530–531 24. Baird DD et al (2015) A prospective, ultrasound-based study to evaluate risk factors for uterine fibroid incidence and growth: methods and results of recruitment. J Womens Health (Larchmt) 24(11):907–915 25. Mahmoud M, Desai K, Nezhat F (2015) Leiomyomas beyond the uterus; benign metastasizing leiomyomatosis with paraaortic metastasizing endometriosis and intravenous leiomyomatosis: a case series and review of the literature. Arch Gynecol Obstet 291(1):223–230 26. Ke ZP et al (2015) Study of effective components and molecular mechanism for Guizhi Fuling formula treatment of dysmenorrhea, pelvic inflammatory disease and uterine fibroids. Zhongguo Zhong Yao Za Zhi 40(6):999–1004 27. Tsigkou A et al (2015) Expression levels of myostatin and matrix metalloproteinase 14 mRNAs in uterine leiomyoma are correlated with dysmenorrhea. Reprod Sci 12:1597–1602 28. Carranza-Mamane B et al (2015) The management of uter ine fibroids in women with otherwise unexplained infertility. J Obstet Gynaecol Can 37(3):277–288 29. Benson CB et al (2001) Outcome of pregnancies in women with uterine leiomyomas identified by sonography in the first trimester. J Clin Ultrasound 29(5):261–264 30. Ekpo GE et al (2014) Knowledge of uterine fibroid symptoms and presentation among African-American women: a pilot study. J Reprod Med 59(9–10):448–454 31. Sharma K et al (2015) Role of 3D ultrasound and doppler in differentiating clinically suspected cases of leiomyoma and adenomyosis of uterus. J Clin Diagn Res 9(4):Qc08-12 32. Jeong EH et al (2013) The relationship between uterine myoma growth and the endocrine disruptor in postmenopausal women. J Menopausal Med 19(3):130–134 33. Ludwin A et al (2013) Transrectal ultrasound-guided hyst eroscopic myomectomy of submucosal myomas with a varying degree of myometrial penetration. J Minim Invasive Gynecol 20(5):672–685 34. Kalayci TO et al (2015) A giant subserosal uterine leiomyoma mimicking an abdominal mass: multimodal imaging data. Acta Med Iran 53(4):246–249 35. Lin G et al (2015) Comparison of the diagnostic accuracy of contrast-enhanced MRI and diffusion-weighted MRI in the differentiation between uterine leiomyosarcoma/smooth muscle tumor with uncertain malignant potential and benign leiomyoma. J Magn Reson Imaging 2:333–342 36. Gupta A, Grunhagen T (2013) Live MR angiographic roadmapping for uterine artery embolization: a feasibility study. J Vasc Interv Radiol 24(11):1690–1697 37. Kayatas S et al (2014) Experience of hysteroscopy indications and complications in 5,474 cases. Clin Exp Obstet Gynecol 41(4):451–454 38. Matytsina-Quinlan L, Matytsina L (2014) Submucosal uterine fibroid prolapsed into vagina in a symptomatic patient with IUS. BMJ Case Report 2014 39. Fridman D, Chakraborty S, Khulpateea N (2011) Fistula between degenerated uterine leiomyoma and the bladder: case report. Int Urogynecol J 22(10):1329–1331

Int Urol Nephrol 40. Kosmidis C et al (2015) Laparoscopic excision of a pedunculated uterine leiomyoma in torsion as a cause of acute abdomen at 10 weeks of pregnancy. Am J Case Rep 16:505–508 41. Rivlin ME et al (1992) Acute urinary retention due to a freestanding broad ligament leiomyoma. J Miss State Med Assoc 33(10):355–357 42. Savolainen S (1989) Allergy in patients with acute maxillary sinusitis. Allergy 44(2):116–122 43. Zaitoon MM (1986) Retroperitoneal parasitic leiomyoma causing unilateral ureteral obstruction. J Urol 135(1):130–131 44. Andrada AO, De Vicente JM, Cidre MA (2014) Pelvic plexus compression due to a uterine leiomyoma in a woman with acute urinary retention: a new hypothesis. Int Urogynecol J 25(3):429–431 45. Bidzinski M et al (2015) Acute urinary retention due to cervical myoma—a case report and a review of the literature. Ginekol Pol 86(1):77–79 46. Yazdany T, Bhatia NN, Nguyen JN (2012) Urinary retention and voiding dysfunction in women with uterine leiomyoma: a case series. J Reprod Med 57(9–10):384–389 47. Derbent A, Turhan NO (2009) Acute urinary retention caused by a large impacted leiomyoma. Arch Gynecol Obstet 280(6):1045–1047 48. Yang JM, Huang WC (2004) Sonographic findings in acute urinary retention secondary to retroverted gravid uterus: pathophysiology and preventive measures. Ultrasound Obstet Gynecol 23(5):490–495 49. Mahdy A, Faruqui N, Ghoniem G (2010) Objective cure of urinary retention following laparoscopic hysterectomy for a large uterine fibroid. Int Urogynecol J 21(5):609–611 50. Mirsadraee S, Tuite D, Nicholson A (2008) Uterine artery embolization for ureteric obstruction secondary to fibroids. Cardiovasc Intervent Radiol 31(6):1094–1099 51. Lai C-C, Chang C-K, Wang J-Y (2009) Hypertension secondary to bilateral hydronephrosis caused by a large uterine myoma. Am J Kidney Dis 54(6):1187 52. Pride GL, Shaffer RL (1977) Nonpuerperal uterine inversion. Report of an unusual case. Obstet Gynecol 49(3):361–364 53. Stewart EA (2015) Clinical practice. Uterine fibroids. N Engl J Med 372(17):1646–1655 54. Parker-Autry C et al (2011) Lower urinary tract symptoms in patients with uterine fibroids: association with fibroid location and uterine volume. Female Pelvic Med Reconstr Surg 17(2):91–96 55. Bettez M et al (2011) Early versus delayed repair of vesicouterine fistula. Can Urol Assoc J 5(4):E52–E55 56. Barr S, McLennan M, Schmitz PG (2009) Acute renal fail ure caused by prolapsed leiomyoma. Obstet Gynecol 114(6):1349–1352 57. Fletcher HM et al (2013) Renal impairment as a complication of uterine fibroids: a retrospective hospital-based study. J Obstet Gynaecol 33(4):394–398 58. Price N et al (2007) Delayed presentation of vesicouterine fistula 12 months after uterine artery embolisation for uterine fibroids. J Obstet Gynaecol 27(2):205–207 59. Masters WH, Johnson VE (1966) Human sexual response. Little, Brown, Boston 60. Berman JR, Adhikari SP, Goldstein I (2000) Anatomy and physiology of female sexual function and dysfunction: classification, evaluation and treatment options. Eur Urol 38(1):20–29 61. Yildiz F et al (2009) A rare cause of difficulty with sexual intercourse: large retroperitoneal leiomyoma. J Sex Med 6(11):3221–3223 62. Giannella L et al (2015) Dyspareunia in a teenager reveals a rare occurrence: retroperitoneal cervical leiomyoma of the left pararectal space. J Pediatr Adolesc Gynecol 1:e9–e11

63. Hamza MA et al (1999) Effect of the frequency of transcutaneous electrical nerve stimulation on the postoperative opioid analgesic requirement and recovery profile. Anesthesiology 91(5):1232–1238 64. Taweel WA, Seyam R (2015) Neurogenic bladder in spinal cord injury patients. Res Rep Urol 7:85–99 65. Funaki K et al (2013) Giant cystic leiomyoma of the uterus occupying the retroperitoneal space. J Radiol Case Rep 7(12):35–40 66. Kim HG et al (2013) A case of torsion of a subserosal leiomyoma. J Menopausal Med 19(3):147–150 67. Dancz C et al (2014) The relationship between uterine leiomyomata and pelvic floor symptoms. Int Urogynecol J 25(2):241–248 68. Rosenfeld H, Byard RW (2012) Lower extremity deep venous thrombosis with fatal pulmonary thromboembolism caused by benign pelvic space-occupying lesions—an overview. J Forensic Sci 57(3):665–668 69. Srettabunjong S (2013) Systemic thromboembolism after deep vein thrombosis caused by uterine myomas. Am J Forensic Med Pathol 34(3):207–209 70. Podduturi V, Armstrong-Briley DR, Guileyardo JM (2014) Sudden death by pulmonary thromboembolism due to a large uterine leiomyoma with a parasitic vein to the mesentery. Case Rep Obstet Gynecol 2014:181265 71. Gupta S, Manyonda IT (2009) Acute complications of fibroids. Best Pract Res Clin Obstet Gynaecol 23(5):609–617 72. Xu HS et al (2013) Uterine leiomyoma extension into right atrium: a case report. J Thorac Cardiovasc Surg 146(3):e13–e14 73. Hawes J et al (2006) Large uterine fibroids causing mechanical obstruction of the inferior vena cava and subsequent thrombosis: a case report. Vasc Endovascular Surg 40(5):425–427 74. Jensen KR (1990) Deep thrombophlebitis in polycythemia and uterine fibromyoma. Ugeskr Laeger 152(32):2316 75. Al Hadidi ST, Mohammed S, Bachuwa G (2015) Unusual presentation of uterine leiomyoma. BMJ Case Report 2015 76. Zyla MM et al (2015) Leiomyomatosis peritonealis disseminata of unusual course with malignant transformation: case report. Acta Obstet Gynecol Scand 94(2):220–223 77. Taylor E, Gomel V (2008) The uterus and fertility. Fertil Steril 89(1):1–16 78. Teramoto S et al (2014) Study on the treatment of pelvic organ prolapse complicated with uterine myoma. Nihon Hinyokika Gakkai Zasshi 105(4):183–189 79. Habek D, Aksamija A (2014) Successful acupuncture treatment of uterine myoma. Acta Clin Croat 53(4):487–489 80. Senol T et al (2015) Levonorgestrel-releasing intrauterine device use as an alternative to surgical therapy for uterine leiomyoma. Clin Exp Obstet Gynecol 42(2):224–227 81. Zhang Y et al (2014) The impact of preoperative gonadotropinreleasing hormone agonist treatment on women with uterine fibroids: a meta-analysis. Obstet Gynecol Surv 69(2):100–108 82. Weingarten TN et al (2014) Lambert-Eaton myasthenic syn drome during anesthesia: a report of 37 patients. J Clin Anesth 26(8):648–653 83. Donnez J et al (2015) Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril 103(2):519-27.e3 84. Chwalisz K et al (2004) Therapeutic potential for the selective progesterone receptor modulator asoprisnil in the treatment of leiomyomata. Semin Reprod Med 22(2):113–119 85. Maggiore ULR et al (2014) Preoperative treatment with letrozole in patients undergoing laparoscopic myomectomy of large uterine myomas: a prospective non-randomized study. Eur J Obstet Gynecol Reprod Biol 181:157–162 86. Ruhnke H et al (2013) MR-guided HIFU treatment of symptomatic uterine fibroids using novel feedback-regulated volumetric ablation: effectiveness and clinical practice. Rofo 185(10):983–991

13

87. Bosteels J et al (2015) Hysteroscopy for treating subfertility associated with suspected major uterine cavity abnormalities. Cochrane Database Syst Rev 2:Cd009461 88. Kroncke T, David M (2015) Uterine Artery Embolization (UAE) for fibroid treatment-results of the 5th radiological gynecological expert meeting. Rofo 187(6):483–485 89. Pieri S et al (2015) Transbrachial approach to the treatment of uterine leiomyomas with embolization of the uterine arteries: a preliminary technical experience. Radiol Med 120(8):759–766 90. Kim YS et al (2014) Techniques to expand patient selection for MRI-guided high-intensity focused ultrasound ablation of uterine fibroids. AJR Am J Roentgenol 202(2):443–451 91. Kong CY et al (2014) MRI-guided focused ultrasound surgery for uterine fibroid treatment: a cost-effectiveness analysis. AJR Am J Roentgenol 203(2):361–371

13

Int Urol Nephrol 92. Bhave Chittawar P et al (2014) Minimally invasive surgical techniques versus open myomectomy for uterine fibroids. Cochrane Database Syst Rev 10:Cd004638 93. Wang CJ et al (2014) Comparison of morcellator and culdotomy for extraction of uterine fibroids laparoscopically. Eur J Obstet Gynecol Reprod Biol 183:183–187 94. Pluchino N et al (2014) Comparison of the initial surgical experience with robotic and laparoscopic myomectomy. Int J Med Robot 10(2):208–212 95. Vilos GA et al (2015) The management of uterine leiomyomas. J Obstet Gynaecol Can 37(2):157–181 96. Waetjen LE et al (2015) Obstacles to studying emerging technologies. Obstet Gynecol 126(2):391–395

Urological complications of uterine leiomyoma: a review of literature.

Uterine leiomyomas are common gynecologic tumor in reproductive-aged women, by age 50, diagnosis shared by urologist, gynecologists and radiologists...
533KB Sizes 1 Downloads 16 Views